content: SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                   -----------------------------------------------
  
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
           Date of report (Date of earliest event reported): June 25, 2004
                                                             -------------
  
                                 CYTOGEN CORPORATION
                ----------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                     000-14879                 22-2322400
  ----------------------------     -----------------------     -------------------
  (State or Other Jurisdiction    (Commission File Number)      (I.R.S. Employer
       of Incorporation)                                       Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ                08540
  ---------------------------------------------------------             ----------
           (Address of Principal Executive Offices)                     (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  
  <PAGE>
  
  
  ITEM 5.     OTHER EVENTS.
  
           On June 25, 2004,  Cytogen  Corporation,  a Delaware  corporation  (the
  "Company")  and Advanced  Magnetics,  Inc.  announced  that  Advanced  Magnetics
  submitted a response to the  approvable  letter  received from the United States
  Food   and   Drug   Administration   for   Combidex(R),    Advanced   Magnetics'
  investigational  molecular  imaging  agent to aid in the diagnosis of metastatic
  lymph nodes.
  
           A copy  of the  related  press  release  of the  Company  and  Advanced
  Magnetics,  dated June 25,  2004,  is filed  herewith  as Exhibit  99.1,  and is
  incorporated herein by reference.  The foregoing description is qualified in its
  entirety by reference to such Exhibit.
  
  ITEM 7.     FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
  
           (c) Exhibits.
  
                Exhibit No.    Description
                -----------    -----------
  
                   99.1        Press release of the Company and Advanced Magnetics
                               dated June 25, 2004.
  
  
  
  <PAGE>
  
  
                                     SIGNATURES
  
  
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly  caused  this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
                                 CYTOGEN CORPORATION
  
  
                                 By:    /s/ Michael D. Becker
                                        ----------------------------------------
                                        Michael D. Becker
                                        President and Chief Executive Officer
  
  Dated:   June 25, 2004
  
  
  
  <PAGE>
  
  
                                    EXHIBIT INDEX
  
  
                Exhibit No.    Description
                -----------    -----------
                   99.1        Press release of the Company and Advanced Magnetics
                               dated June 25, 2004.
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8k_062504.txt", "description": "FORM 8-K DATED JUNE 25, 2004", "secsgml_size_bytes": 3353}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2834", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "04880869"}, "business-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                   -----------------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
           Date of report (Date of earliest event reported): June 25, 2004
                                                             -------------
  
                                 CYTOGEN CORPORATION
                ----------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                     000-14879                 22-2322400
  ----------------------------     -----------------------     -------------------
  (State or Other Jurisdiction    (Commission File Number)      (I.R.S. Employer
       of Incorporation)                                       Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ                08540
  ---------------------------------------------------------             ----------
           (Address of Principal Executive Offices)                     (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  ITEM 5.     OTHER EVENTS.
  
           On June 25, 2004,  Cytogen  Corporation,  a Delaware  corporation  (the
  "Company")  and Advanced  Magnetics,  Inc.  announced  that  Advanced  Magnetics
  submitted a response to the  approvable  letter  received from the United States
  Food   and   Drug   Administration   for   Combidex(R),    Advanced   Magnetics'
  investigational  molecular  imaging  agent to aid in the diagnosis of metastatic
  lymph nodes.
  
           A copy  of the  related  press  release  of the  Company  and  Advanced
  Magnetics,  dated June 25,  2004,  is filed  herewith  as Exhibit  99.1,  and is
  incorporated herein by reference.  The foregoing description is qualified in its
  entirety by reference to such Exhibit.
  
  ITEM 7.     FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
  
           (c) Exhibits.
  
                Exhibit No.    Description
                -----------    -----------
  
                   99.1        Press release of the Company and Advanced Magnetics
                               dated June 25, 2004.
  SIGNATURES
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly  caused  this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
                                 CYTOGEN CORPORATION
  
                                 By:    /s/ Michael D. Becker
                                        ----------------------------------------
                                        Michael D. Becker
                                        President and Chief Executive Officer
  
  Dated:   June 25, 2004
  EXHIBIT INDEX
  
                Exhibit No.    Description
                -----------    -----------
                   99.1        Press release of the Company and Advanced Magnetics
                               dated June 25, 2004.